Abstract
The effectiveness of current treatments against lung cancer is limited, among other factors, by ineffective targeting, low solubility in water and rapid elimination of antineoplastics such as doxorubicin (DOX). Furthermore, the non-specificity of these bioactive molecules results in systemic side effects due to the toxicity they present in healthy cells in the body. To overcome these adve…